NPPB and type 2 diabetes mellitus: Liraglutide improved diastolic cardiac function mainly in a bodyweight reduction-dependent manner, but it significantly contributed to BNP reduction in a bodyweight reduction-independent manner in patients with type 2 diabetes with preserved ejection fraction.